A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) (NCT06941272)
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment The study treatment HER3-DXd (also known as MK-1022 or patritumab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of HER3-DXd in children and if they tolerate it * What happens to HER3-DXd in children's bodies over time * If children who receive HER3-DXd have the cancer get smaller or go away
Who can join: Review the eligibility criteria below.
Location: Childrens Hospital Los Angeles ( Site 3006) — Los Angeles, California
Age range: 1 Month to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (54 Sites)
Showing the first 25 of 54 sites.
- Childrens Hospital Los Angeles ( Site 3006) — Los Angeles, California
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 3016) — Aurora, Colorado
- Johns Hopkins All Children's Hospital ( Site 3025) — St. Petersburg, Florida
- University of Iowa Health Care Holden Comprehensive Cancer Center ( Site 3017) — Iowa City, Iowa
- Dana-Farber Cancer Institute ( Site 3013) — Boston, Massachusetts
- Corewell Health ( Site 3001) — Grand Rapids, Michigan
- Children's Mercy Hospital ( Site 3024) — Kansas City, Missouri
- Rutgers Cancer Institute of New Jersey ( Site 3008) — New Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center ( Site 3010) — New York, New York
- New York Medical College ( Site 3023) — Valhalla, New York
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3003) — Fargo, North Dakota
- Oregon Health and Science University ( Site 3004) — Portland, Oregon
- Children's Hospital of Philadelphia (CHOP) ( Site 3021) — Philadelphia, Pennsylvania
- Sanford Children's Hospital ( Site 3015) — Sioux Falls, South Dakota
- University of Texas-MD Anderson Cancer Center ( Site 3007) — Houston, Texas
- Intermountain - Primary Children's Hospital ( Site 3014) — Salt Lake City, Utah
- Sydney Children's Hospital-Kids Cancer Centre ( Site 3997) — Sydney, New South Wales
- Queensland Children's Hospital ( Site 3996) — Brisbane, Queensland
- UZ Gent ( Site 3428) — Ghent, Oost-Vlaanderen
- Fundação Pio XII - Hospital de Câncer de Barretos ( Site 3264) — Barretos, São Paulo
- Hospital Pablo Tobon Uribe ( Site 3923) — Medellín, Antioquia
- Clinica de la Costa S.A.S. ( Site 3924) — Barranquilla, Atlántico
- IMAT S.A.S ( Site 3921) — Montería, Departamento de Córdoba
- Detska nemocnice FN Brno ( Site 3388) — Brno, Brno-mesto
- Fakultni nemocnice v Motole-Klinika detske hematologie a onkologie ( Site 3387) — Prague, Praha 5
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Malignant Neoplasm
- Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment — Duarte, California
- Reproductive Health Program in Patients With Cancer — Jonesboro, Arkansas
- rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy — Houston, Texas
- Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer — Newark, Delaware
- Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families — Houston, Texas
- Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies — Los Angeles, California
Explore by condition: All Malignant Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.